文献速递甲状腺疾病垂体与肾上腺疾病

Sod2诱导的氧化应激改变影响内分泌肿瘤进展

Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

该研究通过转录组分析及小鼠模型,探讨锰超氧化物歧化酶(MnSod/SOD2)在内分泌肿瘤预后与进展中的作用。结果发现SOD2在滤泡性甲状腺癌中下调且低表达与侵袭性甲状腺或肾上腺癌患者生存较差相关;Sod2过表达在良性甲状腺肿瘤中增加肿瘤负荷,但在侵袭性滤泡性甲状腺癌中抑制增殖并改善死亡率,而Sod2缺失则促进肿瘤生长。结论提示SOD2在肿瘤进展中具有双相、情境依赖的作用。

要点

  • SOD2在滤泡性甲状腺癌中下调,低表达与侵袭性甲状腺或肾上腺癌患者生存较差相关。
  • Sod2过表达在良性甲状腺肿瘤中增加肿瘤负荷,在侵袭性滤泡性甲状腺癌中抑制增殖并改善死亡率。
  • Sod2缺失在侵袭性滤泡性甲状腺癌中促进肿瘤生长,提示其作用具有情境依赖性。

核心结论

  • SOD2在内分泌肿瘤进展中具有双相作用,且作用方式具有情境特异性。

研究设计与样本

  • 研究对人和小鼠内分泌癌模型进行转录组分析。
  • 研究将Sod2无效等位基因或转基因Sod2过表达等位基因引入良性甲状腺滤泡性肿瘤或侵袭性转移性滤泡性甲状腺癌(FTC)小鼠模型,监测肿瘤起始和进展的表型变化。

主要发现

  • 在甲状腺中,SOD2/Sod2在滤泡性甲状腺癌中下调,但在甲状腺乳头状癌中未下调。
  • SOD2表达降低与侵袭性甲状腺癌或肾上腺癌患者生存较差相关。
  • 在良性甲状腺肿瘤小鼠中,Sod2过表达增加肿瘤负荷。
  • 在侵袭性滤泡性甲状腺癌小鼠中,Sod2过表达减少肿瘤增殖并改善死亡率,而Sod2缺失增强肿瘤生长。

临床怎么用

  • SOD2表达状态可能有助于判断侵袭性甲状腺癌或肾上腺癌患者的预后风险。
  • 针对SOD2的干预需考虑肿瘤类型和分期,避免在良性甲状腺肿瘤中因过表达而增加肿瘤负荷。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Although important advances have been made in understanding the genetics of endocrine tumors, cellular physiology is relatively understudied as a determinant of tumor behavior. Oxidative stress and reactive oxygen species are metabolic factors that may affect tumor behavior, and these are, in part, controlled by manganese-dependent superoxide dismutase (MnSod), the mitochondrial superoxide dismutase (encoded by SOD2). OBJECTIVE: We sought to understand the role of MnSod in the prognosis of aggressive human endocrine cancers and directly assessed the effect of MnSod under- or overexpression on tumor behavior, using established mouse thyroid cancer models. METHODS: We performed transcriptome analysis of human and mouse models of endocrine cancer. To address the role of Sod2 in endocrine tumors, we introduced a Sod2 null allele or a transgenic Sod2 overexpression allele into mouse models of benign thyroid follicular neoplasia or aggressive, metastatic follicular thyroid cancer (FTC) and monitored phenotypic changes in tumor initiation and progression. RESULTS: In the thyroid, SOD2/Sod2 was downregulated in FTC but not papillary thyroid cancer. Reduced expression of SOD2 was correlated with poorer survival of patients with aggressive thyroid or adrenal cancers. In mice with benign thyroid tumors, Sod2 overexpression increased tumor burden. In contrast, in mice with aggressive FTC, overexpression of Sod2 reduced tumor proliferation and improved mortality rates, whereas its deficiency enhanced tumor growth. CONCLUSION: Overall, our results indicate that SOD2 has dichotomous roles in cancer progression and acts in a context-specific manner.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ashtekar A, Huk D, Magner A, et al. Alterations in Sod2-Induced Oxidative Stress Affect Endocrine Cancer Progression. J Clin Endocrinol Metab. 2018. PMID: 30165401. doi:10.1210/jc.2018-01039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。